Document Detail


Chronic oral ascorbic acid therapy worsens skeletal muscle metabolism in patients with chronic heart failure.
MedLine Citation:
PMID:  17023203     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chronic heart failure (CHF) is associated with abnormalities of skeletal muscle metabolism. This may be due to impaired oxygen delivery as a result of endothelial dysfunction.
AIMS: We postulated that ascorbic acid would improve oxygen delivery to exercising muscle and improve skeletal muscle metabolism.
METHODS: We studied skeletal muscle metabolism using (31)P magnetic resonance spectroscopy in 39 CHF patients. Endothelial function was assessed by changes in pulse wave velocity. Subjects were randomised to receive 4 g ascorbic acid daily for 4 weeks in a placebo-controlled double-blind study.
RESULTS: Ascorbic acid significantly increased phosphocreatine utilization during exercise. In addition, glycolytic ATP synthesis increased in the ascorbic acid group (change in rate of ATP synthesis at 1 min -0.21+/-0.76 with placebo, 2.06+/-0.60 following ascorbic acid; p<0.05). Phosphocreatine and ADP recovery after exercise were not changed. The fall in pulse wave velocity during reactive hyperaemia was increased by ascorbic acid from -6.3+/-2.6% to -12.1+/-2.0% (p<0.05).
CONCLUSIONS: These findings suggest that ascorbic acid increased both phosphocreatine utilization and glycolytic ATP synthesis during exercise in patients with CHF implying worsened skeletal muscle metabolism despite improvements in endothelial function.
Authors:
Angus K Nightingale; Jenifer G Crilley; Nicholas C Pegge; Ernie A Boehm; Catherine Mumford; Doris J Taylor; Peter Styles; Kieran Clarke; Michael P Frenneaux
Related Documents :
15470653 - Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted ...
18834463 - Atrial fibrillation is associated with decreased cardiac sympathetic response to isomet...
12373493 - Fulminant japanese spotted fever definitively diagnosed by the polymerase chain reactio...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-10-04
Journal Detail:
Title:  European journal of heart failure     Volume:  9     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-05     Completed Date:  2007-06-19     Revised Date:  2011-06-08    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  287-91     Citation Subset:  IM    
Affiliation:
Bristol Heart Institute, Bristol University, Bristol, UK. drangus@doctors.org.uk <drangus@doctors.org.uk>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Triphosphate / biosynthesis
Aged
Ascorbic Acid / blood,  therapeutic use*
Chronic Disease
Double-Blind Method
Endothelium, Vascular / drug effects*,  physiopathology
Female
Great Britain
Heart Failure / metabolism*,  physiopathology
Humans
Magnetic Resonance Spectroscopy
Male
Middle Aged
Muscle, Skeletal / drug effects*,  metabolism
Phosphocreatine / metabolism
Chemical
Reg. No./Substance:
50-81-7/Ascorbic Acid; 56-65-5/Adenosine Triphosphate; 67-07-2/Phosphocreatine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4.
Next Document:  International variations in the treatment and co-morbidity of left ventricular systolic dysfunction:...